Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus

Jia Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoyan Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Haoran Zhang(Urban Planning & Design Institute of Shenzhen (China)), Dongming Zhang(Heilongjiang Bayi Agricultural University), Jing Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuequan Shi(Chinese Academy of Medical Sciences & Peking Union Medical College)
Translational Oncology
July 26, 2022
10.1016/j.tranon.2022.101473
Cited by 25

Related Papers

Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
|The Lancet Oncology|2012|228
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
|PLoS ONE|2015|206
Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE
|European Radiology|2021|140
Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin
|Circulation Research|2004|114